Vulvovaginal candidosis - PubMed (original) (raw)
Review
Vulvovaginal candidosis
Jack D Sobel. Lancet. 2007.
Abstract
Despite therapeutic advances, vulvovaginal candidosis remains a common problem worldwide, affecting all strata of society. Understanding of anti-candida host defence mechanisms in the vagina has developed slowly and, despite a growing list of recognised risk factors, a fundamental grasp of pathogenic mechanisms continues to elude us. The absence of rapid, simple, and inexpensive diagnostic tests continues to result in both overdiagnosis and underdiagnosis of vulvovaginal candidosis. I review the epidemiology and pathogenesis of this infection, and also discuss management strategies.
Similar articles
- Recurrent vulvovaginal candidiasis.
Sobel JD. Sobel JD. Am J Obstet Gynecol. 2016 Jan;214(1):15-21. doi: 10.1016/j.ajog.2015.06.067. Epub 2015 Jul 9. Am J Obstet Gynecol. 2016. PMID: 26164695 Review. - Facts and myths on recurrent vulvovaginal candidosis--a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy.
Mårdh PA, Rodrigues AG, Genç M, Novikova N, Martinez-de-Oliveira J, Guaschino S. Mårdh PA, et al. Int J STD AIDS. 2002 Aug;13(8):522-39. doi: 10.1258/095646202760159639. Int J STD AIDS. 2002. PMID: 12194734 Review. - [Fungal diseases of vulva and vagina caused by Candida species].
Stock I. Stock I. Med Monatsschr Pharm. 2010 Sep;33(9):324-33; quiz 335-6. Med Monatsschr Pharm. 2010. PMID: 21192442 Review. German. - Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society.
Mendling W, Brasch J; German Society for Gynecology and Obstetrics; Working Group for Infections and Infectimmunology in Gynecology and Obstetrics; German Society of Dermatology, the Board of German Dermatologists; German Speaking Mycological Society. Mendling W, et al. Mycoses. 2012 Jul;55 Suppl 3:1-13. doi: 10.1111/j.1439-0507.2012.02185.x. Mycoses. 2012. PMID: 22519657 - [Treatment of recurrent vulvovaginal candidosis with mycosyst (fluconazole)].
Pekhlivanov B, Amaliev I, Ivancheva Kh, Zisova L. Pekhlivanov B, et al. Akush Ginekol (Sofiia). 2005;44 Suppl 2:25-7. Akush Ginekol (Sofiia). 2005. PMID: 16028400 Bulgarian.
Cited by
- Anticandidal Activity of Omiganan and Its Retro Analog Alone and in Combination with Fluconazole.
Czechowicz P, Jaśkiewicz M, Neubauer D, Gościniak G, Kamysz W. Czechowicz P, et al. Probiotics Antimicrob Proteins. 2021 Aug;13(4):1173-1182. doi: 10.1007/s12602-021-09757-9. Epub 2021 Mar 2. Probiotics Antimicrob Proteins. 2021. PMID: 33655458 Free PMC article. - Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections.
Muzny CA, Schwebke JR. Muzny CA, et al. Clin Infect Dis. 2015 Aug 15;61(4):601-6. doi: 10.1093/cid/civ353. Epub 2015 May 1. Clin Infect Dis. 2015. PMID: 25935553 Free PMC article. Review. - Molecular Characterization of Highly Susceptible Candida africana from Vulvovaginal Candidiasis.
Yazdanparast SA, Khodavaisy S, Fakhim H, Shokohi T, Haghani I, Nabili M, Gholami H, Ahmadi I, Badali H. Yazdanparast SA, et al. Mycopathologia. 2015 Dec;180(5-6):317-23. doi: 10.1007/s11046-015-9924-z. Epub 2015 Jul 17. Mycopathologia. 2015. PMID: 26183965 - Increased Activities against Biofilms of the Pathogenic Yeast Candida albicans of Optimized Pom-1 Derivatives.
Amann V, Kissmann AK, Krämer M, Krebs I, Perez-Erviti JA, Otero-Gonzalez AJ, Morales-Vicente F, Rodríguez A, Ständker L, Weil T, Rosenau F. Amann V, et al. Pharmaceutics. 2022 Jan 28;14(2):318. doi: 10.3390/pharmaceutics14020318. Pharmaceutics. 2022. PMID: 35214049 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources